U.S. FDA accepts Biogen’s marketing application for its Alzheimer’s drug
A scientist works in a lab at Biogen in Cambridge, MA on Nov. 5, 2016.
Suzanne Kreiter | Boston Globe | Getty Images
Biogen and Japan’s Eisai said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer’s disease treatment aducanumab.
If approved, aducanumab would become the first therapy to reduce the clinical decline associated with Alzheimer’s disease.
The FDA has set a date of March 7 for taking a decision on the treatment.